Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome-Reference-Cited by-同舟云学术

Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome

Published:2016-06-20 Issue:10 Volume:76 Page:1031-1040
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Garnock-Jones Karly P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-016-0601-4.pdf

Reference41 articles.

1. Bogan RK. From bench to bedside: an overview of rotigotine for the treatment of restless legs syndrome. Clin Ther. 2014;36(3):436–55.

2. Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. Postgrad Med J. 1053;2013(89):402–10.

3. Trenkwalder C, Winkelmann J, Inoue Y, et al. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434–45.

4. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385–96.

5. European Medicines Agency. Leganto® (rotigotine transdermal patch): EU summary of product characteristics. 2011. http://www.ema.europa.eu/ . Accessed 14 Mar 2016.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo staging of colitis, adenoma and carcinoma in CRC progression by combination of H4R/DRD4-targeted fluorescent probes;European Journal of Medicinal Chemistry;2024-09

2. Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome;Expert Review of Neurotherapeutics;2024-07-31

3. Available Treatment Modules for Brain Disorders;Food Bioactive Ingredients;2023

4. How effective are treatment guidelines for augmented RLS?;Sleep;2022-05-09

5. ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine;Expert Review of Neurotherapeutics;2020-09-01